No Data
Amphastar Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Amphastar Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results.
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $66
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript Summary
Amphastar Pharmaceuticals Non-GAAP EPS of $0.96 Misses by $0.02, Revenue of $191.2M Misses by $3.49M
No Data
No Data
